AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06387160 — intervention group
Intervention type: DRUG
Intervention: as per institutional protocol
Description: This is an observational study. Treatment will be given to the patients as per institutional protocol
Study NCT06066801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bedside blind bone biopsy procedure
Description: It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
Study NCT06066801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside blind bone biopsy procedure
Description: It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
Study NCT03800082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: at heart (changed from HEARTPA♀N during usability testing)
Description: An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
Study NCT05489237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDRX-42
Description: Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
Study NCT05671679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAQ app
Description: SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
Study NCT05671679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional carbohydrate counting
Description: Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
Study NCT04763031 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative Radiation Therapy - IORT
Description: Single dose of 20 Gy
Study NCT05642949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHB036C
Description: MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
Study NCT06348979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns
Description: restoration of endodontically treated teeth by endocrowns
Study NCT06348979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: all ceramic Endocrowns (emax)
Description: restoration of endodontically treated teeth by endocrowns
Study NCT05492292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perfusion brain scintigraphy imaging
Description: The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
Study NCT05686993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Description: Cinnarizine oral 30mg TDS
Study NCT05686993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIFEdipine ER
Description: Nifedipine oral 60mg daily extended release
Study NCT05665387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% STN1013600 ophthalmic solution
Description: 0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
Study NCT05665387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% STN1013600 ophthalmic solution
Description: 0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
Study NCT05665387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution 1 drop BID for 2 months
Study NCT04908020 — intervention group
Intervention type: OTHER
Intervention: Follow-up patients
Description: The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rematazolam Besylate
Description: Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
Study NCT06398795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).
Description: An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.
Study NCT06398795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional open thyroidectomy (COT)
Description: open thyroidectomy with traditional collar incisions
Study NCT06104371 — intervention group
Intervention type: DEVICE
Intervention: Magtrace
Description: Sentinel lymph node tracer and metastatic lymph node clip
Study NCT05022264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RIA-VS
Description: Measuring vital signs with a new contactless camera technique
Study NCT05875103 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: linguistic processes
Description: Linguistic processes are assessed by performance score on the following tests:~* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~* vocabulary test (Mill Hill - Deltour, 1993),~* repetition tests (Gremots - Bézy et al., 2016),~* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)
Study NCT05616715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peek device
Description: Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
Study NCT05616715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crown lengthening/gingivectomy
Description: Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
Study NCT04807829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Nabilone is a synthetic endocannabinoid and CB1 agonist.
Study NCT04807829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo comparator
Study NCT06013488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Character Strengths Based Coaching Support
Description: Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks
Study NCT06013488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Supervision
Description: Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)
Study NCT06013488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Supervision
Description: Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
Study NCT05768269 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
Study NCT04883346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
Study NCT05190549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAV regimen bridging to HSCT
Description: The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
Study NCT06375330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoliArt
Description: PoliArt injections
Study NCT04529538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Oral Polio Vaccine Type 1 (nOPV1)
Description: Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
Study NCT04529538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Oral Polio Vaccine Type 3 (nOPV3)
Description: Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
Study NCT05616065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinding to academic performance of candidate
Description: Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
Study NCT05616065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Interview methodology
Description: Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
Study NCT06030895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tablets
Description: Sorafenib Tablets (200 -400 mg) twice daily
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study NCT05624424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study NCT05330780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Room
Description: 8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
Study NCT05907694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Description: Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
Study NCT05907694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
Study NCT05068661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.1% Injectable Solution
Description: DPE
Study NCT05068661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: CSE
Study NCT04529538 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)
Description: The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
Study NCT06074822 — intervention group
Intervention type: OTHER
Intervention: Residual neuromuscular biopsy
Description: recovery of residual neuromuscular biopsy (nerve ans muscle)
Study NCT06560450 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stride One
Description: Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
Study NCT04529538 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
Description: the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.
Study NCT06528431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinical tapering strategy
Description: Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
Study NCT06528431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step Wedge trial
Description: Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
Study NCT05002478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: Turn patient in prone position after surfactant administration.
Study NCT04001114 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Sampling Research Cigarettes
Description: Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
Study NCT05515874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use.
Study NCT06075004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Local Anesthetic Infiltration
Description: Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
Study NCT06075004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block
Description: From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle.
Study NCT02658292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftifine hydrochloride foam, 3%
Description: Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
Study NCT02658292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
Study NCT06298370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block plus intrathecal bupivacaine
Description: Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Study NCT06134609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Description: Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D
Description: Tablet given orally
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide G
Description: Tablet given orally